Previous 10 | Next 10 |
BOSTON, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm. Ziopharm also intends to ...
The CAR-T landscape is replete with different permutations of the technology that are often arcane and difficult to grasp for even seasoned investors. Each formulation has its own advantages and disadvantages critical to understand in order to get a decent hold on a company’s long term ...
– Encouraging long-term outcome data after infusion of Sleeping Beauty -modified CAR-T published in Blood – – TCRs targeting mutations in TP53 obtained from T cells in peripheral blood to overcome need for surgical resection published in Clinical Cancer Research ...
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with this Read more ...
BOSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco on...
– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON, Dec. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc....
Enochian Biosciences ( ENOB ) is hands down the craziest and most overvalued biotech that we’ve ever seen. Our initial report on Enochian has shaken things up within the company, and more developments have occurred that make the story even more bizarre. We discuss these new developm...
JanOne (NASDAQ: JAN ) +127% on acquiring worldwide license for treatment of Peripheral Arterial Disease. More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Medicines Company, Stocks on the move, Read more ...
– Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects – – Controlled IL-12 can be combined with full dose of a PD-1 inhibitor; favorab...
BOSTON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that the Company’s presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019, has been moved to 1:20 p.m. GMT (8:20 a.m. ET). To access the live webcast ...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...